Image source: WuXi PharmaTech WeChat public number Today (May 8th), the pharmaceutical industry unicorn enterprise WuXi PharmaTech officially listed on the main board of Shanghai stock market, the daily limit at the opening, the price of 31.10 yuan, an increase of 43.98%, reaching the first increase limit of the listing, the total market value reached 32.406 billion yuan. Image source: Snowball According to previous reports, WuXi PharmaTech has updated from pre-disclosure on February 6 to the meeting. It took only 50 days, second only to Foxconn, which had already had a quick meeting in the previous 36 days, and after more than half a month. , WuXi PharmaTech succeeded in "anti-super" Foxconn, the first to get an IPO approval. However, WuXi PharmaTech’s listing fundraising scale has shrunk. The amount of funds raised by the company’s initial prospectus is 5.74 billion yuan, but it was subsequently adjusted to 2.13 billion yuan, which is much higher than the previous plan. 63%. Despite this, the scale of the issue has not changed, which means that the company chooses to issue at a lower P/E ratio, leaving more room for the secondary market. As a result, some analysts said that WuXi PharmaTech's listing will bring good returns to the winners. At present, WuXi PharmaTech's CSI industry's P/E ratio is about 65 times, and WuXi PharmaTech's P/E ratio is 22.99 times. 6 yuan / share issuance, if the price-earnings ratio reaches 65 times open, there are about 8 consecutive daily limit. If it is 8 daily limit, the profit per medium can be close to 40,000 yuan; if the daily limit reaches 16, it will become the first new stock in the year with a winning income of over 100,000. On the evening of May 6, WuXi PharmaTech disclosed financial data for the first quarter of 2018. According to the data, WuXi PharmaTech achieved operating income of 2.14 billion yuan in the first quarter of 2018, an increase of 21.1% year-on-year. situation. However, what is embarrassing is that although the net profit in the first quarter was 260 million yuan, it fell 8.5% year-on-year. In response, a person in charge of WuXi PharmaTech responded that the main reason for the decline in net profit after deduction was that the exchange gains and losses arising from the appreciation of the renminbi led to the company's first quarter financial expenses compared with the previous year. Increased in the same period. Excluding the impact of exchange gains and losses resulting from the above exchange rate appreciation, the company's net profit attributable to issuer shareholders increased by 14.9% compared with the same period last year. At the same time, just before the listing of WuXi PharmaTech, the Internet medical “unicorn†enterprise was safe and the doctor broke. The safe doctor was listed on the Hong Kong Stock Exchange on May 4, and it was closed at 54.8 on the day of listing. In Hong Kong dollars, the increase is an astonishing "0%". On the second trading day, Ping An’s doctor closed at HK$52.75 and the speed of breaking was amazing.
Our PP Resin is used to manufacture various port with different models, such as Single Port, Double Port ,Small Port etc . We have a excellent supply-chain in our product materials. If you have any specific requirements, let us know, we will do our best to meet your requirements.In our website,we provide the images and basic parameters for each products. We are a professional chinese manufacturer of medical packaging and look forward to your inquiries! Pp Resin For Port,Polypropylene Pp Copolymer Resin,Pp Granules Pp Resin,Pp Pellets Pp Resin Suzhou CRH New Material Technology Co.,Ltd. , https://www.crh-health.com
